The UK Government has published the first set in a series of technical notes for businesses and members of the public on how to prepare for the possibly the UK leaves the EU without securing a withdrawal agreement. These guidance notes cover importing and exporting, workplace rights, regulating medicines and medical equipment, farming, product safety, EU-funded programmes including Horizon 2020, state aid, studying in the UK or EU, money and tax and civil nuclear and nuclear research. More documents are planned.
The European Commission’s preparedness notices on these and other policy areas also looks at the consequences of the UK’s withdrawal from the European Union under various scenarios.
If you are interested in this from a Scottish perspective the SPICe blog from the Scottish Parliament Information Centre intends to provide analysis on the UK Government’s technical notes over the next month.
Yesterday it was announced that the European Medicines Agency will relocate from London to Amsterdam. The EMA is an agency of the European Union and its role involves the scientific evaluation, supervision and safety monitoring of medicines for human and animal use as well as assisting national agencies authorise medicine sales within the EU single market.
The EMA has to relocate due to the UK decision to leave the EU and the UK Government’s desire to no longer be subject to the jurisdiction of the European Court of Justice.
EMA has been based in London, UK, since it’s location was secured by John Major’s government in 1995, the year the Agency was established. It currently employs nearly 900 people with a further 36,000 scientists and regulators visiting each year.
A House of Commons Library Research Paper entitled Brexit and medicines regulationlooks at how medicines are currently regulated in the UK, the role of the EMA and what the options are post Brexit.